10-Q: BioLargo Reports Q1 2025 Results: Revenue Declines Amid Ongoing Efforts to Commercialize Cleantech Innovations

BioLargo's Q1 2025 revenue decreased by 31% compared to Q1 2024, primarily due to lower sales of its private-label pet odor control product, while the company continues to invest in the development and commercialization of its cleantech technologies.

Summary

• BioLargo, Inc. reported a 31% decrease in revenue for the three months ended March 31, 2025, totaling $3.269 million compared to $4.760 million in the same period of 2024.
• The decrease in revenue is primarily attributed to a decline in sales of the Pooph-branded pet odor control product, which accounted for 79% of the company's consolidated revenues.
• The company's net loss increased to $1.921 million, or $ (0.004) per share, compared to a net loss of $775,000, or $ (0.001) per share, for the same period in the previous year.
• ONM Environmental's revenue decreased by 39% to $2.803 million, while BLEST's revenue increased by 152% to $466,000.
• As of March 31, 2025, BioLargo had current assets of $7.218 million, including $2.564 million in cash and cash equivalents, and current liabilities of $3.373 million, resulting in working capital of $3.845 million.
• The company used $1.830 million in net cash for operating activities during the three months ended March 31, 2025.
• BioLargo and its subsidiaries received $885,000 from financing activities, including sales of stock and the issuance of note payables.
• The company expresses substantial doubt about its ability to continue as a going concern without increasing revenues, generating cash from operations or financing activities, converting assets to cash, or reducing cash obligations.
• The company is focused on commercializing its cleantech technologies, including the AEC for PFAS remediation, AROS for water reuse, and CellinityTM battery energy storage system.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with some positive developments in certain business segments but overall negative financial results and concerns about the company's ability to continue as a going concern. The reliance on a single product for a significant portion of revenue and the increasing net loss contribute to the low sentiment score.

Positives

• BLEST's revenue increased by 152% due to new contracts for air quality control compliance services at U.S. Air Force bases, generating approximately $100,000 per month.
• BioLargo is actively pursuing the commercialization of its AEC PFAS treatment technology, with a key project in New Jersey awaiting completion of other facilities.
• BETI is developing the Cellinity battery technology for long-duration energy storage, with preliminary testing confirming key performance claims.
• BioLargo has secured channel partner agreements with several sales representative organizations ensuring coverage for most of the continental United States for the AEC technology.
• BioLargo is in the early stages of developing a collaboration with the US EPA to have its AEC technology validated through a rigorous third-party pilot study.

Negatives

• BioLargo's Q1 2025 revenue decreased by 31% compared to Q1 2024, primarily due to lower sales of its private-label pet odor control product, Pooph.
• The company's net loss increased to $1.921 million, or $ (0.004) per share, compared to a net loss of $775,000, or $ (0.001) per share, in the same period last year.
• ONM Environmental's revenue decreased by 39% to $2.803 million.
• The company expresses substantial doubt about its ability to continue as a going concern.
• Clyra Medical has not yet begun commercial sales of its products and thus did not generate revenues in the three months ended March 31, 2025 or 2024.

Risks

• The company's reliance on a single private-label product (Pooph) for a significant portion of its revenue makes it vulnerable to fluctuations in that product's sales.
• The company's statement about its ability to continue as a going concern raises concerns about its financial stability.
• The lengthy sales cycles for advanced water treatment systems could delay revenue generation from BEST.
• BLEST needs to hire more qualified staff to meet and expanding demand for our growing list of customers and/or expected customers.
• The company's success is dependent on the successful commercialization of its technologies, which is subject to various risks and uncertainties.

Future Outlook

The company expects a decrease in ONM Environmental's revenues for the three months ending June 30, 2025, compared with the same period in 2024. The company expresses substantial doubt about its ability to continue as a going concern without increasing revenues, generating cash from operations or financing activities, converting assets to cash, or reducing cash obligations.

Industry Context

BioLargo operates in the cleantech industry, which is focused on developing and commercializing technologies that address environmental challenges. The company's activities span several sub-sectors, including water treatment, odor control, and energy storage. The company faces competition from established players in each of these markets, as well as from other emerging cleantech companies. The company's success depends on its ability to develop and commercialize innovative technologies that offer a competitive advantage over existing solutions.

Comparison to Industry Standards

• It's difficult to directly compare BioLargo's results to industry standards due to its diverse range of activities and its focus on developing and commercializing novel technologies.
• However, the company's revenue decline and net loss are concerning, particularly in light of its statement about its ability to continue as a going concern.
• Companies like Xylem and Evoqua Water Technologies are established players in the water treatment industry with significantly larger revenue bases and more diversified product portfolios.
• In the battery technology space, companies like QuantumScape and Solid Power are focused on developing next-generation battery technologies, but they are also facing challenges in scaling up production and achieving commercial viability.
• BioLargo's success will depend on its ability to execute its commercialization strategy and demonstrate the value proposition of its technologies to customers.

Stakeholder Impact

• Shareholders: The decrease in revenue and increase in net loss could negatively impact shareholder value.
• Employees: The company's concerns about its ability to continue as a going concern could create uncertainty for employees.
• Customers: The company's focus on commercializing its technologies could lead to new and improved products and services for customers.
• Suppliers: The company's financial challenges could impact its ability to pay suppliers in a timely manner.
• Creditors: The company's financial challenges could increase the risk for creditors.

Next Steps

• The company intends future water treatment projects to be contracted through BEST.
• The company is working to obtain technology validation from an independent organization for its Cellinity batteries.
• The company is exploring multiple opportunities to commercialize its proprietary liquid sodium batteries through joint ventures with third parties.

Key Dates

Keywords

BioLargo, revenue, net loss, PFAS, AEC, Cellinity, ONM Environmental, BLEST, Clyra Medical, water treatment, odor control, battery technology, financial results, going concern